|
|
Volumn 102, Issue 3, 2010, Pages 148-151
|
|
Japan works to shorten "drug lag," boost trials of new drugs.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
NEW DRUG;
ARTICLE;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG INDUSTRY;
ECONOMICS;
EDUCATION;
EVIDENCE BASED MEDICINE;
GOVERNMENT;
HUMAN;
INTERDISCIPLINARY COMMUNICATION;
INTERNATIONAL COOPERATION;
JAPAN;
NATIONAL HEALTH ORGANIZATION;
OFF LABEL DRUG USE;
PATIENT CARE;
PERSONNEL;
POLICY;
TIME;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUGS, INVESTIGATIONAL;
EVIDENCE-BASED MEDICINE;
GOVERNMENT AGENCIES;
HUMANS;
INTERDISCIPLINARY COMMUNICATION;
INTERNATIONAL COOPERATION;
JAPAN;
NATIONAL CANCER INSTITUTE (U.S.);
NATIONAL INSTITUTES OF HEALTH (U.S.);
OFF-LABEL USE;
PATIENT CARE TEAM;
PUBLIC POLICY;
RESEARCH PERSONNEL;
TIME FACTORS;
UNITED STATES;
|
|
EID: 77449111052
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djq017 Document Type: Article |
|
Times cited : (18)
|
|
References (0)
|
